MAPK3 and melanoma: Treatment-naïve melanoma cells were sensitive to IGF1-R inhibition but ERK1/2i-resistant cells much more so, like their increased sensitivity to ERK5 pathway inhibition; indeed, ERK5 activation in resistant cells was IGF1-R-dependent (Figure 3).